A study in women with breast cancer suggests that low oral doses of minoxidil, taken during or after cancer treatment, appear to regrow hair in most patients and without causing any serious heart-related side effects that require additional therapies or hospitalization.
Researchers at Baylor College of Medicine and Rice University received a $2.3 million Breakthrough Award from the Department of Defense Congressionally Directed Medical Research Programs to develop a novel NanoGel antibody therapy that targets ER+ breast cancer that has metastasized to bone.
RWE and phase I data support the role of Orserdu for ER+, HER2- advanced or metastatic breast cancer
The Menarini Group and Stemline Therapeutics will present new and expanded data on Orserdu at the upcoming 2024 San Antonio Breast Cancer Symposium, held from Dec. 10-13. The company will bring real-world progression-free survival results of Orserdu in adult patients with ER+/HER2-, advanced or metastatic breast cancer. Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase Ib/2 of both the ELECTRA and ELEVATE trials.
A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.
FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”
The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.
New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.
Six Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium scientists received $1.7M in grants from Breast Cancer Research Foundation to launch or continue studies aimed at improving outcomes in breast cancer.
New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in... […]
Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they’ve escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop cancer recurrence, and one—MUC1—is already in clinical trials. The research was published online Sept. 28 in... […]
